Bionor Immuno Company Profile: Acquisition & Investors

Description

Developer of vaccines. The company creates peptides which are used in vaccines to cause production of desired antibodies.

Contact Information

Website

Ownership Status

Acquired/Merged

Financing Status

Corporate Backed or Acquired

Primary Industry

Pharmaceuticals

Acquirer

Primary Office

What you see here scratches the surface

We’ll help you find what you need

Deal Type	Date	Amount	Valuation/ EBITDA	Post-Val	Status	Debt

This information is available in the PitchBook Platform. To explore Bionor Immuno‘s full profile, request access.

Publication ID	Patent Title	Status	First Filing Date	Technology (CPC)
ES-2296793-T3	Hiv peptides of conserved regions, tat, rev and wef and its application as for example components of vaccine.	Inactive	04-Sep-2000	0000000000
US-7097971-B2	Novel peptides based on conserved regions of regulatory and auxiliary hiv proteins, antigens in free or carrier-bound form comprising one of the peptides, vaccine compositions containing one of the antigens, immunoassay kits and a method of detecting antibodies, induced by hiv using such antigens	Inactive	04-Sep-2000	0000000000
US-20050053616-A1	Peptides based on conserved regions of regulatory and auxiliary hiv proteins, antigens in free or carrier-bound form comprising one of the peptides, vaccine compositions containing one of the antigens, immunoassay kits and a method of detecting antibodies, induced by hiv using such antigens	Active	04-Sep-2000	0000000000
AU-8633601-A	Hiv regulatory and auxiliary peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv	Pending	04-Sep-2000	0000000000
AU-2001286336-B2	Hiv peptides from tat, rev and wef conserved and their application as e.g. vaccine components	Inactive	04-Sep-2000	C07K14/005